CSL Behring announced the availability of DNA1 Advanced Alpha-1 Screening (DNA1), a test designed to improve the diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1). 

DNA1 is a comprehensive Alpha-1 test that identifies known and unknown clinically relevant genetic variants.

RELATED: Diagnostic Agents Resource Center

Alpha-1 is a serious hereditary condition that can cause lung disease and/or liver disease. It is often misdiagnosed as COPD, asthma or emphysema because the symptoms are similar: shortness of breath, chronic cough, difficulty breathing, and wheezing. 

The American Thoracic Society and European Respiratory Society recommend screening adults with COPD, emphysema, or irreversible asthma for Alpha-1–associated emphysema.

DNA1 offers test results for the following:

  • Clinical chemistry – Blood spot assay to test patient alpha-1 antitrypsin (AAT) levels, as well as a C-reactive protein (CRP) test to provide full clinical analysis
  • Targeted genotyping – Identifies all known, clinically relevant variants, including S, Z, and F
  • Next generation sequencing – Sequencing of the SERPINA1 gene to identify unknown variants
  • Isoelectric focus – Results compared to genetic results as a confirmatory step   

For more information call (888) 508-6978 or visit CSLBehring.com.